Changing the landscape in
Life-Threatening Diseases

^aOmaveloxolone is approved by the US FDA. ^bDiabetic peripheral neuropathic pain (DPNP). ^cChronic Kidney Disease (CKD). ^dAutosomal Dominant Polycystic Kidney Disease (ADPKD). ^eBardoxolone methyl (bardoxolone). On February 25, 2022, we received a Complete Response Letter from the Food and Drug Administration (FDA). We will continue to work with the FDA to confirm our next steps on our Alport syndrome program. ^fAYAME study conducted in Japan by our strategic collaborator in CKD, Kyowa Kirin.

Omaveloxolone is an investigational drug not approved by any other regulatory authority. Bardoxolone methyl, and RTA 901 are investigational drugs. Safety and efficacy have not been established by any agency.